These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23730507)

  • 1. A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer.
    Lloyd S; Chang BW
    J Gastrointest Oncol; 2013 Jun; 4(2):123-30. PubMed ID: 23730507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer.
    Mancini BR; Stein S; Lloyd S; Rutter CE; James E; Chang BW; Lacy J; Johung KL
    J Gastrointest Oncol; 2018 Dec; 9(6):982-988. PubMed ID: 30603116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.
    Choi Y; Oh DY; Kim K; Chie EK; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Ha SW; Bang YJ
    Cancer Res Treat; 2016 Jul; 48(3):1045-55. PubMed ID: 26511805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative chemoradiation and IOERT for unresectable or borderline resectable pancreas cancer.
    Ashman JB; Moss AA; Rule WG; Callister MG; Reddy KS; Mulligan DC; Collins JM; De Petris G; Gunderson LL; Borad M
    J Gastrointest Oncol; 2013 Dec; 4(4):352-60. PubMed ID: 24294506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
    Trinh KV; Fischer DA; Gardner TB; Smith KD
    Front Oncol; 2020; 10():1461. PubMed ID: 33042792
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer.
    Ma SJ; Hermann GM; Prezzano KM; Serra LM; Iovoli AJ; Singh AK
    Cancer Med; 2019 Mar; 8(3):939-952. PubMed ID: 30652417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.
    Wo JY; Niemierko A; Ryan DP; Blaszkowsky LS; Clark JW; Kwak EL; Lillemoe KD; Drapek LN; Zhu AX; Allen JN; Faris JE; Murphy JE; Nipp R; Fernandez-Del Castillo C; Ferrone CR; Hong TS
    Am J Clin Oncol; 2018 Jul; 41(7):656-661. PubMed ID: 28134673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who benefited most from higher cumulative dose of cisplatin among patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiation therapy? A retrospective study of 527 cases.
    Ou X; Xu T; He X; Ying H; Hu C
    J Cancer; 2017; 8(14):2836-2845. PubMed ID: 28928873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer.
    Ma SJ; Iovoli AJ; Hermann GM; Prezzano KM; Singh AK
    Cancer Med; 2019 Aug; 8(9):4110-4123. PubMed ID: 31183965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J; Thephamongkhol K
    BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer.
    Shrestha B; Sun Y; Faisal F; Kim V; Soares K; Blair A; Herman JM; Narang A; Dholakia AS; Rosati L; Hacker-Prietz A; Chen L; Laheru DA; De Jesus-Acosta A; Le DT; Donehower R; Azad N; Diaz LA; Murphy A; Lee V; Fishman EK; Hruban RH; Liang T; Cameron JL; Makary M; Weiss MJ; Ahuja N; He J; Wolfgang CL; Huang CY; Zheng L
    Cancer Med; 2017 Jul; 6(7):1552-1562. PubMed ID: 28639410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
    Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
    J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].
    Sano T; Takano K; Chiba N; Tomita K; Ozawa Y; Hikita K; Shimazu M; Kawachi S
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1488-90. PubMed ID: 26805072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery.
    Kim MM; Mansfield PF; Das P; Janjan NA; Badgwell BD; Phan AT; Delclos ME; Maru D; Ajani JA; Crane CH; Krishnan S
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):167-72. PubMed ID: 18406886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
    Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
    Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
    Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis.
    Yoo C; Shin SH; Kim KP; Jeong JH; Chang HM; Kang JH; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Ryoo BY; Kim SC
    Cancers (Basel); 2019 Feb; 11(3):. PubMed ID: 30813624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.